A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer.
- Author:
Gun Hi KANG
1
;
Gwang Sil KIM
;
Hyo Rak LEE
;
Young Jin YUH
;
Sung Rok KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Inje University, Sanggye Paik Hospital, Seoul, Korea. srkjoy@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach Neoplasms;
Chemotherapy;
Paclitaxel;
5-fluorouracil;
Cisplatin
- MeSH:
Cisplatin;
Drug Therapy, Combination;
Fluorouracil;
Humans;
Neutropenia;
Paclitaxel;
Stomach Neoplasms;
Stomatitis;
Thrombocytopenia
- From:Cancer Research and Treatment
2008;40(3):106-110
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. MATERIALS AND METHODS: Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m2 on day 1, 5-FU 1 g/m2/ day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m2 on day 1 were administered. This regimen was repeated every 3 weeks. RESULTS: A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0~77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed. CONCLUSIONS: The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.
